India to seek latest data on efficacy of Gilead’s Remdesivir following USFDA nod

-


 India’s drug regulatory authority will seek data from US-based Gilead Sciences on the latest finding on the effectiveness of its antiviral drug remdesivir in Covid-19 patients, after the US drug regulator approved it as treatment for the disease.


Remdesivir is the first drug to be cleared by the US Food and Drug Administration for treating Covid-19. The formal approval came on Thursday. While the move indicates that the drug is safe and effective for people hospitalised with Covid-19, India’s Central Drugs Standard Control Organisation (CDSCO) wants to assess the data before making a decision.

“We will be writing to Gilead Sciences to understand the latest evidence on the effectiveness of the drug. We will then review and assess and take any further decision in this regard,” said a senior official of CDSCO.

The antiviral drug, administered intravenously, is already under assessment in India, officials said, in the wake of new evidence by the World Health Organisation (WHO) which suggested that remdesivir appears to have little effect on mortality of hospitalised patients.

We can’t blindly follow any other country. We have to keep under consideration the results of the solidarity trial too,” the official said.

The FDA had granted remdesivir emergency authorisation in May after a trial by the National Institutes of Health found that it modestly reduced the recovery time in people hospitalised with Covid-19. US President Donald Trump, too, received the antiviral drug after he began showing symptoms earlier this month.

Comments

Post a Comment

Popular posts from this blog

India’s health budget fourth lowest in world, accoring to Oxfam

-
  India’s health budget fourth lowest in world, accoring to Oxfam Afghanistan and India set aside the same share for health in their budgets, 4%, just above a quarter of the recommended spending and one-third of what the second poorest country in the world, Burundi, did. And that may have affected how far people were shielded from the Covid-19 outbreak, the latest ‘Commitment to Reducing Inequality Index 2020’ by international charity Oxfam says.
Read more

Lee Kun-hee, who made S.Korea's Samsung a global powerhouse, dies at 78

-
Image
  Lee Kun-hee, who built Samsung Electronics into a global powerhouse in smartphones, semiconductors and televisions, died on Sunday after spending more than six years in hospital following a heart attack, the company said. The charismatic leader of Samsung Group and the country's richest person, grew it into South Korea’s biggest conglomerate. But he and the empire he built have also been vilified by critics for wielding huge economic clout, and for opaque governance and dubious transfer  of the family wealth. "Lee is such a symbolic figure in South Korea's spectacular rise and how South Korea embraced globalisation, that his death will be remembered by so many Koreans," said Chung Sun-sup, chief executive of corporate researcher firm Chaebul.com. Lee, who was 78, is the latest second-generation leader of a South Korean family-controlled conglomerate, or chaebol, to die, leaving potentially thorny succession issues for the third generation.
Read more

BANK Q & A -9

-
Image
  81. Which of the following contracts involves future exchange of assets at a specified price? [A] future contract [B] forward contract [C] Present contract [D] Spot contract Hide Answer Correct Answer:  B [forward contract] Notes: A forward contract is a private agreement between two parties giving the buyer an obligation to purchase an asset (and the seller an obligation to sell an asset) at a set price at a future point in time. 82. Which of the following is best described as selling a synthetic asset and simultaneously buying the actual asset? [A] Arbitrage [B] Diversifying [C] Speculating [D] Hedging Hide Answer Correct Answer:  A [Arbitrage] Notes: Arbitrage is the simultaneous purchase and sale of an asset to profit from an imbalance in the price. It is a trade that profits by exploiting the price differences of identical or similar financial instruments on different markets or in different forms. 83. Which of the following indicates the wealth of a person? [A] Ba...
Read more